Spartalizumab

Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune system's ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs) [1][2].

Product Specifications

CAS Number

[1935694-88-4]

Product Name Alternative

PDR001

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/spartalizumab.html

Purity

99.50

Solubility

H2O

Smiles

[Spartalizumab]

Molecular Weight

(143.14 kDa)

References & Citations

[1]Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38 (23) :2620-2627.|[2]Naing A, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020 Mar;8 (1) :e000530.